Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes Mellitus, Type 2: full-pipeline trial registry
63 of 351 indexed Diabetes Mellitus, Type 2 trials are currently recruiting.
Corpus placement: #18 of 28,707 conditions by registered trial count.
351 US clinical trials · 63 currently recruiting · #18 of 28,707 conditions by registered trial count
Diabetes Mellitus, Type 2: 351 US clinical trials tracked, 63 recruiting.
Diabetes Mellitus, Type 2 is the subject of 351 registered US clinical trials on ClinicalTrials.gov, 63 of them currently open to new participants. 100 are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 48 of these trials.
Enrollment posture brief
Registry condition diabetes-mellitus-type-2
OPEN 63 | RECR 18% | LATE 100 | EARLY 80 | RANK #18 | SPON 48
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (18% recruiting · 39 trials)
Diabetes Mellitus, Type 2 lists 63 open slots (18% of 351 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes Mellitus, Type 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes Mellitus, Type 2 is recruiting below its size-band peers.
63 of 351 indexed trials (17.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetes Mellitus, Type 2 trials is spread across many organizations.
Novo Nordisk A/S accounts for 48 of 351 trials (13.7%). 143 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetes Mellitus, Type 2 enrolment sits around 150 participants.
Median target enrolment is 150 among the 349 trials that report a genuine target (sentinel values excluded). 142 of those (40.7%) plan for fewer than 100 participants.
-
Diabetes Mellitus, Type 2 research is mostly interventional.
321 interventional and 30 observational studies make up this index (91.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
351 total, page 3 of 8
Self-Management and Glycemic Control in Adult Haitian Immigrants With Type 2 Diabetes
New York University
NCT04949568
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
MediciNova
NCT05464784
Short Interval Resveratrol Trial in Cardiovascular Surgery
MaineHealth
NCT03762096
ADAM17 and Vascular Function in Diabetes
University of Missouri-Columbia
NCT04557228
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Stony Brook University
NCT05666479
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen Research & Development
NCT03492580
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims
Brigham and Women's Hospital
NCT06659744
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
Boehringer Ingelheim
NCT05465317
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
Brigham and Women's Hospital
NCT06914102
Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims
Brigham and Women's Hospital
NCT06659679
Evaluation of a Dashboard for Diabetes Care Integrated With the Electronic Health Record
University of Utah
NCT03826290
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
National Heart, Lung, and Blood Institute (NHLBI)
NCT00000620
Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants
Novo Nordisk A/S
NCT02608853
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Eli Lilly and Company
NCT01394952
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Novo Nordisk A/S
NCT01959529
INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
Novo Nordisk A/S
NCT00101751
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Novo Nordisk A/S
NCT03819153
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)
Sanofi
NCT02451137
Improving Patient Prioritization During Hospital-homecare Transition
Columbia University
NCT04136951
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01336023
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Novo Nordisk A/S
NCT03078478
Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone
AstraZeneca
NCT00121667
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
Novo Nordisk A/S
NCT05352815
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
Novo Nordisk A/S
NCT02648204
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
Janssen Research & Development
NCT01809327
A National Study of the Chronic Disease Self-Management Program
Stanford University
NCT01845857
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT02128932
A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease
Duke University
NCT03936660
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
GlaxoSmithKline
NCT00838903
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
Novo Nordisk A/S
NCT00972283
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
Novo Nordisk A/S
NCT04460885
A Study in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
NCT01064687
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Sanofi
NCT02738151
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
Novo Nordisk A/S
NCT01819129
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim
NCT01370005
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT02863328
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01885208
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
Eli Lilly and Company
NCT01126580
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
Takeda
NCT01023581
Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)
Sanofi
NCT00653341
The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)
Janssen Research & Development
NCT01137812
US Inhaled Insulin Therapeutic Choice Questionnaire Study
Pfizer
NCT00139763
Enhancing Self-Management Support in Diabetes Through Patient Engagement
University of California, San Francisco
NCT02834923
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT02863419
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
Novo Nordisk A/S
NCT05259033
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
Hoffmann-La Roche
NCT00754988
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT00700817
Dapagliflozin Patient Satisfaction Survey
AstraZeneca
NCT02805283
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01923181
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
GlaxoSmithKline
NCT00329225
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 42 |
| Phase 2 | 38 |
| Phase 3 | 74 |
| Phase 4 | 26 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes Mellitus, Type 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes Mellitus, Type 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes Mellitus, Type 2 page
351 registered trials, 63 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 63 Diabetes Mellitus, Type 2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Diabetes Mellitus, Type 2 trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus, Type 2 condition card totals 351 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.